Detail akcie Repligen Corp online

Business Summary: Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Repligen Corp revenues increased less than 1% to $634.4M. Net loss totaled $25.5M vs. income of $35.6M. Revenues reflect Product revenue - Filtration products segment increase of 9% to $373M, Product revenue-Process analytics products segment increase of 4% to $59.3M, North America segment increase of 14% to $317.2M, also reflect Product revenue - Protein products segment decrease of 28% to $74.4M.